Protection against MIS-C outweighs the risk of myocarditis after Covid-19 vaccination in children

Ital J Pediatr. 2022 Aug 4;48(1):142. doi: 10.1186/s13052-022-01335-1.

Abstract

From March 2020 to July 2022, in Liguria region (North-West Italy) incidence of MIS-C among pediatric patients infected by SARS-CoV-2 was 38.7/100.000, which is higher than that of myocarditis after COVID-19 vaccination. In our opinion severity of MIS-C-related cardiac disease outweigh the risk of myocarditis after COVID-19 vaccine.

Keywords: BNT162b2; Children; Vaccine.

Publication types

  • Letter

MeSH terms

  • COVID-19 Vaccines* / adverse effects
  • COVID-19 Vaccines* / therapeutic use
  • COVID-19* / prevention & control
  • Child
  • Humans
  • Italy
  • Myocarditis* / chemically induced
  • SARS-CoV-2
  • Systemic Inflammatory Response Syndrome* / prevention & control
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related